Legend Biotech (LEGN) Capital Leases (2024 - 2025)
Legend Biotech (LEGN) posted quarterly Capital Leases of $51.7 million for Q1 2025, up 15.94% on a QoQ basis from $44.6 million in Q4 2024.
Legend Biotech (LEGN) Capital Leases (2024 - 2025) Analysis & Trends
Legend Biotech (LEGN) has reported Capital Leases for 2 consecutive years, with $51.7 million the latest figure, recorded in Q1 2025.
- Quarterly Capital Leases changed N/A year-over-year to $51.7 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $51.7 million (changed N/A YoY) and the FY2024 annual result came in at $44.6 million, changed N/A from the prior year.
- Capital Leases improved to $51.7 million in Q1 2025 per LEGN's latest filing, from $44.6 million in the prior quarter.
- Over the last five years, Capital Leases for LEGN reached as high as $51.7 million in Q1 2025 and fell as low as $44.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Legend Biotech | 8.69 Bn | 7.79 Bn | 129.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 51.72 Mn |
| Dec 31, 2024 | 44.61 Mn |